Ianalumab
Ianalumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target tumor necrosis factor ligand superfamily member 13B and tumor necrosis factor receptor superfamily member 13C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | 2 | 5 | 3 | — | — | 9 |
| Syndrome | D013577 | — | — | 1 | 4 | 3 | — | — | 7 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 1 | 2 | 3 | — | — | 6 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 1 | 2 | — | — | 3 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | 2 | — | — | 3 |
| Autoimmune hepatitis | D019693 | — | — | — | 1 | 1 | — | — | 1 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 1 | 1 | — | — | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 1 | 1 | — | — | 1 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | — | 1 | — | — | 1 |
| Nephritis | D009393 | — | N05 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 1 | — | — | — | 3 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 2 | 1 | — | — | — | 3 |
| Sclerosis | D012598 | — | — | — | 2 | — | — | — | 2 |
| Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | 1 | 1 | — | — | — | 2 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | 1 | — | — | — | 1 |
| Hidradenitis | D016575 | — | — | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | — | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 2 | — | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | — | — | — | — | 1 |
| Follicular lymphoma | D008224 | — | C82 | 1 | — | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | — | 1 | — | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | — | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ianalumab |
| INN | ianalumab |
| Description | Ianalumab (INN; development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies; narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594357 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | ZN2GQ3II96 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TNFSF13B
TNFSF13B
TNFRSF13C
TNFRSF13C
Organism
Homo sapiens
Gene name
TNFSF13B
Gene synonyms
BAFF, BLYS, TALL1, TNFSF20, ZTNF4
NCBI Gene ID
Protein name
tumor necrosis factor ligand superfamily member 13B
Protein synonyms
ApoL related ligand TALL-1, B lymphocyte stimulator, B-cell-activating factor, B-lymphocyte stimulator, BAFF, BLyS, CD257, delta BAFF, Delta4 BAFF, Dendritic cell-derived TNF-like molecule, epididymis secretory sperm binding protein, TALL-1, TNF and ApoL-related leukocyte expressed ligand 1, TNF homolog that activates apoptosis, TNF- and APOL-related leukocyte expressed ligand 1, tumor necrosis factor (ligand) superfamily, member 13b, tumor necrosis factor (ligand) superfamily, member 20, tumor necrosis factor ligand 7A, tumor necrosis factor superfamily member 13b, tumor necrosis factor-like protein ZTNF4
Uniprot ID
Mouse ortholog
Tnfsf13b (24099)
tumor necrosis factor ligand superfamily member 13B (Q9WU72)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 197 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use